Sana Biotechnology, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Sana Biotechnology, Inc. (SANA) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- Sana Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$295.00K, a 146.97% decline year-over-year.
- Sana Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.63M.
- Sana Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $696.00K.
- Sana Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.12M.
- Sana Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$1.17M, a 133.16% decline from fiscal 2024.
- Sana Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $3.51M.
- Sana Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$8.14M, a 235.99% decline from fiscal 2022.
- Sana Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $5.99M, a 595.47% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$295.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.92M 10-Q · filed 2026-08-10 | -$1.23M derived: sum of 3 quarters · filed 2026-08-10 | -$2.35M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$1.63M 10-Q · filed 2026-05-11 | -$932.00K derived: sum of 2 quarters · filed 2026-05-11 | -$2.05M derived: sum of 3 quarters · filed 2026-05-11 | -$1.43M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $696.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$425.00K derived: sum of 2 quarters · filed 2026-03-03 | $203.00K derived: sum of 3 quarters · filed 2026-08-10 | -$1.17M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$493.00K derived: sum of 2 quarters · filed 2026-08-10 | -$1.86M 10-Q · filed 2025-11-06 | -$5.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $628.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$740.00K 10-Q · filed 2026-08-10 | -$4.01M derived: sum of 3 quarters · filed 2026-08-10 | -$4.69M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$1.37M 10-Q · filed 2026-05-11 | -$4.64M derived: sum of 2 quarters · filed 2026-05-11 | -$5.31M derived: sum of 3 quarters · filed 2026-05-11 | -$235.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$3.95M derived: sum of 2 quarters · filed 2026-03-03 | $1.13M derived: sum of 3 quarters · filed 2026-03-03 | $3.51M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$678.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.40M derived: sum of 2 quarters · filed 2025-11-06 | $6.78M 10-Q · filed 2025-11-06 | $4.20M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $5.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $7.46M 10-Q · filed 2025-08-11 | $4.88M derived: sum of 3 quarters · filed 2026-03-03 | $4.74M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $2.38M 10-Q · filed 2025-05-08 | -$203.00K derived: sum of 2 quarters · filed 2026-03-03 | -$335.00K derived: sum of 3 quarters · filed 2026-03-03 | -$5.87M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$2.71M derived: sum of 2 quarters · filed 2026-03-03 | -$8.25M derived: sum of 3 quarters · filed 2026-03-03 | -$8.14M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$132.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$5.67M derived: sum of 2 quarters · filed 2024-11-08 | -$5.56M 10-Q · filed 2024-11-08 | $997.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | -$5.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$5.43M 10-Q · filed 2024-08-08 | $1.13M derived: sum of 3 quarters · filed 2025-03-17 | -$97.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $106.00K 10-Q · filed 2024-05-08 | $6.66M derived: sum of 2 quarters · filed 2025-03-17 | $5.44M derived: sum of 3 quarters · filed 2025-03-17 | $2.90M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $5.33M derived: sum of 2 quarters · filed 2025-03-17 | $2.80M derived: sum of 3 quarters · filed 2025-03-17 | $5.99M 10-K · filed 2025-03-17 |
| 2022-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$3.76M derived: sum of 2 quarters · filed 2023-11-08 | -$569.00K 10-Q · filed 2023-11-08 | -$2.69M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $657.00K 10-Q · filed 2023-08-03 | -$1.47M derived: sum of 3 quarters · filed 2024-02-29 | -$201.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $3.19M 10-Q · filed 2023-05-08 | $1.07M derived: sum of 2 quarters · filed 2024-02-29 | $2.33M derived: sum of 3 quarters · filed 2024-02-29 | $2.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$858.00K derived: sum of 2 quarters · filed 2024-02-29 | -$753.00K derived: sum of 3 quarters · filed 2024-02-29 | $861.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $1.37M derived: sum of 2 quarters · filed 2022-11-02 | $2.98M 10-Q · filed 2022-11-02 | $5.10M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.72M 10-Q · filed 2022-08-04 | $3.84M derived: sum of 3 quarters · filed 2023-03-16 | $3.58M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $1.61M 10-Q · filed 2022-05-10 | $3.73M derived: sum of 2 quarters · filed 2023-03-16 | $3.47M derived: sum of 3 quarters · filed 2023-03-16 | $2.55M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.86M derived: sum of 2 quarters · filed 2023-03-16 | $935.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.44M 10-K · filed 2023-03-16 |
| 2020-09-30 | -$259.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$1.18M derived: sum of 2 quarters · filed 2021-11-08 | -$682.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$924.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$423.00K 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $501.00K 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $4.30M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |